This clinical trial is focused on studying a condition called Generalized Myasthenia Gravis, which is a chronic autoimmune disease that causes muscle weakness. The study is investigating a treatment called Rozanolixizumab, also known by its code name UCB7665. Rozanolixizumab is given as a solution for injection under the skin, a method known as subcutaneous use. The purpose of the study is to assess the safety and how well this treatment is tolerated in children aged 2 to under 18 years who have moderate to severe generalized myasthenia gravis.

Participants in the study will receive Rozanolixizumab over a period of six weeks. During this time, researchers will monitor how the drug moves through the body and its effects on the disease. The study will also look at any side effects that may occur, including serious ones that might lead to stopping the treatment. Additionally, the study will measure changes in certain proteins in the blood, known as immunoglobulins, and specific antibodies related to myasthenia gravis. These measurements will help determine if the treatment is working and how it affects the participants’ daily activities and overall condition.

The study is designed to last up to 18 weeks, including the treatment and observation periods. Throughout the study, researchers will evaluate the local tolerability of the treatment, which means they will check how the skin and body react to the injections. The study aims to provide valuable information on the potential benefits and risks of using Rozanolixizumab in young patients with generalized myasthenia gravis, contributing to better understanding and management of this condition.